# NOTIFICATION OF APPLICATION

## Receipt of licence application from the University of Tasmania for a trial of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils.

The Office of the Gene Technology Regulator (OGTR) has received a licence application (DIR 195) from the University of Tasmania to conduct a trial with a genetically modified (GM) adenoviral vaccine to protect Tasmanian devils against devil facial tumour disease.A summary of the application is posted on our [website](https://www.ogtr.gov.au/what-weve-approved/dealings-involving-intentional-release) (search for DIR 195).

The purpose of the trial is to evaluate the immunogenicity, safety and efficacy of the GM vaccine for the prevention and/or treatment of devil facial tumour disease. The GM vaccine would be administered to Tasmanian devils kept in enclosures within trial sites in Tasmania.

The OGTR is preparing a Risk Assessment and Risk Management Plan for the application. This is expected to be released for public comment and advice from experts, agencies and authorities in **March 2023.** There will be at least 30 days for submission of comments.

If you have any questions or would like to receive a copy of the full application or the summary, please contact the OGTR and quote the reference number DIR 195.

**Office of the Gene Technology Regulator MDP 54 GPO Box 9848 CANBERRA ACT 2601**

**Telephone: 1800 181 030 E-mail:** [**ogtr@health.gov.au**](mailto:ogtr@health.gov.au)

[OGTR website](http://www.ogtr.gov.au/)

Dr Raj Bhula

Gene Technology Regulator

30 January 2023